All News

psoriasis,arms,pain

IL-23 Blockade Goes Oral

d Aurelie Najm, MD, PhD

A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the interleukin-23 receptor (IL-23R), is showing encouraging efficacy and safety across a range of psoriasis (PSO) and psoriatic disease (PsD) studies.

Read Article
eyes

Sjogren’s disease: two drugs with positive trials

d Md Yuzaiful Md Yusof, MRCP(UK), PhD

After several failures of therapies in Phase 3 trials of Sjogren’s disease (SjD) over many years, all hope is not lost!

Read Article
cost.healthcare.jpg

Beyond the Breakthrough: Equity and Access in CAR-T Cell Therapy for RA

d Bella Mehta, MBBS, MS

At ACR Convergence 2025, abstract 1039 entitled, “Global Cost-Effectiveness and Equity in CAR-T Cell Therapy for Rheumatoid Arthritis” adds a critical dimension to the growing enthusiasm around cellular therapies in autoimmune disease.

Read Article
What happens if you have #axSpA & concomitant #FM? Pts with both have less TNFi retention, -residual pain may lead to d/c Rx. Need to determine if axSpA pt has #fibromyalgia as there may not be objective findings if no peripheral arthritis in axSpA. #ACR25 @RheumNow abst#534

Janet Pope Janetbirdope ( View Tweet)

Post-CAR-T myelopathy has been an issue in heme onc, and is still an unpredictable quantity without a clear cause. Will this be a problem for autoimmune CAR-T as we gain more experience? @CarolineDiorio @ChildrensPhila in the #ACR25 BCRC pre-meeting @RheumNow https://t.co/RhhdOiyEAX

Links:

David Liew drdavidliew ( View Tweet)
When should you order a renal bx in suspected #LN? Active urinary sediment Used to be #UPCR 500g/g or more Abst#772 looked at UPCR 250g/g to 499 71% + LN and half needed Rx esp if Low C3,C4 Black race Petri, Baltimore #lupus #cohort #ACR25 @ACRheum @RheumNow

Janet Pope Janetbirdope ( View Tweet)

RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

Next Generation T-Cell Engager: The Future Dr. Alfred Kim reviews abstract 0001 presented at #ACR25. https://t.co/vmZYfmKCm8 https://t.co/PkLOs9lZ8l

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is selected by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

CAR-T Cell Therapies Show Promise for Autoimmune Disease Two pioneering studies presented at #ACR25 spotlight the potential of CAR-T cell therapies to transform treatment for SLE and other autoimmune diseases. These early findings suggest a new frontier in immune modulation and https://t.co/KdNWmVc4Qc
Dr. John Cush RheumNow ( View Tweet)
ACR2025 Day 4 Recap https://t.co/YaWB9iVMsy

Links:

Dr. John Cush RheumNow ( View Tweet)

Meta analysis evaluating age specific incidence across multiple registries (n=882) Incidence 9.3 for women & 1.4 for men per 100k person-years 1. Wider distribution than I would have guessed 2. Much less age-dependency for men @RheumNow #ACR25 Abstr#29W06 https://t.co/46dNGBZ45V

Links:

Mike Putman EBRheum ( View Tweet)
Phase 1 study of CAR-Treg in difficult to treat RA 4/6 pts had 50% reduction in TJC/SJC, no CYC/fludrabine required & good prelim safety data CAR-T remains exciting, but less of the "totally magical everyone cured" stuff we saw w/initial CAR-T reports @RheumNow #ACR25 https://t.co/kjBIkLCYpF

Links:

Mike Putman EBRheum ( View Tweet)
"Achieving good control of joint disease activity is probably the key objective of treatment of patients with RA-ILD" - Gregory McDermott (Epi Abstracts, #2662) Totally agree with this! SARD guidelines recommendingn drugs with mediocre activity in RA was surprising @RheumNow

Mike Putman EBRheum ( View Tweet)

Excited about this target trial emulation in RA-ILD Compared to RTX, NO significant difference in hospitalization/transplant/death for JAK, ABA, IL6 or TNF Trends toward ABA and JAK looking better than RTX Need trials for sure, but I like this project a lot @RheumNow #ACR25 https://t.co/FQcphRvyHK

Links:

Mike Putman EBRheum ( View Tweet)
In AxSpA, an 8-week personalized exercise program improved trunk strength (+14.1%), mobility (+14.9%), and cardiorespiratory fitness ( increased oxygen pulse, ventilatory efficiency, anaerobic threshold). BASDAI and chest expansion also improved. Supports tailored rehab based on https://t.co/jawosa2AJK

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#Ianalumab decreases disease activity in active #Sjögren's #disease 2 phase3 DB #RCT added to #SoC in primary #SjD >90% #Ro+ +#ESSDAI in monthly sc dosing vs placebo, Many 2ndary outcomes improved, safe LB#24 #ACR25 @ACRheum @RheumNow #ACRBest https://t.co/Z4ooUg7Nos

Links:

Janet Pope Janetbirdope ( View Tweet)
In a PsA cohort (n=1291), higher BMI was independently linked to lower odds of achieving MDA—especially in TNFi-treated patients. Impact was strongest in pain, skin, enthesitis, and PRO domains, not swollen joints. Each unit increase in BMI reduced MDA odds by 4–7%. Highlights https://t.co/TxO3HP51uk

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#2686 Using HR-pQCT, researchers tracked bone changes in RA & PsA. Seropositive RA showed worst bone density & microstructure, worsening with disease activity. TNFi, RTX & BARI improved MCP bone density, highlighting the impact of inflammation and treatment. @RheumNow #ACR25

Mrinalini Dey DrMiniDey ( View Tweet)

Will CAR-Treg Rx be helpful in active #refractory #rheumatoid #arthritis? Early data n=6 treated w low dose (3 per arm), ongoing and doses will escalate Improvemt in #clinical #disease #activity less inflammation on #synovial #biopsies 3 pts #LB23 #ACR25 @RheumNow @ACRheum https://t.co/PkhsvztVjx

Links:

Janet Pope Janetbirdope ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×